ESCMID COVID-19 living guidelines: drug treatment and clinical management.

Clin Microbiol Infect · 2022 · PMC8606314 · PMID 34823008

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the first dataset of BLAZE-1, bamlanivimab showed a trend towards decreased viral load vs. placebo with a significant difference for the 2800-mg dose [ 30 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.